Biology:GABRA2
Generic protein structure example |
Gamma-aminobutyric acid receptor subunit alpha-2 is a protein in humans that is encoded by the GABRA2 gene.[1]
GABRA2 is an alpha subunit that is part of GABA-A receptors, which are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain, GABA. Chloride conductance of these channels can be modulated by agents, such as benzodiazepines (psychoactive drugs) that bind to the GABA-A receptor.
GABA-A receptors are composed of two alpha, two beta, and one gamma subunits. They have at least 16 distinct subunits identified, including GABRA2.[2] This receptor is found mainly in specific regions of the brain, such as the hippocampus.[3]
Subunit isoforms are seen around in various locations in the brain throughout growth. The combination of subunits has a large effect on the pharmacological and biophysical characteristics.[4] GABRA2 has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control. Most of GABRA2 modifications have been found to be linked to alcoholism and adolescent behavior.
Structure
GABRA2 is one of the 16 distinct alpha subunits found for the GABA receptor. GABA-A has a pentametric form, with two alpha, two beta, and one gamma subunit.[3] The various subunit isoforms seen in the GABA-A receptor structure has an effect on its function. GABRA2 is most often seen as part of the most common expression α2β3γ2, which is seen in 13% of all GABA-A receptors.[4] The subunit, GABRA2, is found primarily in hippocampus and/or the forebrain. It is more confined to areas of the brain in comparison to other alpha subunits seen in GABA-A receptors. It is present in 35% of all GABA-A receptors being the fourth most abundant subunit next to GABRA1 and various beta subunits. Like all subunits, it is made from structurally distinct proteins. The presence of this subunit causes an easier binding of benzodiazepine which is a category of psychoactive drugs.[3]
Function
GABRA2 mediates neural activity necessary for information processing in inter-neurons.[3] GABRA2 participates in transporting Cl− ions into the membrane, since it forms part of the GABA-A receptor. The influx of Cl− causes the hyper-polarization of the membrane, leading to inhibitory actions.
GABRA2 increases the risk of anxiety making it a target for treating behavioral disorders.[5] Some examples of behavioral disorders include anxiety, alcohol dependence, and drug use. GABRA2 is a binding site for benzodiazepines. Benzodiazepines are psychoactive drugs known to reduce anxiety. Benzodiazepines bind to GABRA2 causing chloride channels to open, leading to the hyper-polarization of the membrane.[6] Other anxiolytic drugs like Diazepam target this alpha subunit in GABA-A to induce inhibitory effects.[3]
GABRA2 is associated with reward behavior when it activates the insula.[5] The insula is part of the cerebral cortex responsible for emotions. GABRA2 role in reward behavior explains the higher risk of alcohol dependence and drug use behavior.
Clinical significance
Since GABRA 2 mediates anxiolytic activity, it is a key receptor for emotional control. Several developmental stages of GABRA2 have shown effects on behavior such as adult alcohol dependence and adolescent behavior.
Alcoholism
Since GABRA 2 subunit mediates anxiolytic activity, long term use or withdrawal of ethanol can cause dependence alterations in the GABA-A receptor.[3]
When alcohol is present in the brain, it affects two types of receptors: GABA-A, inhibitory receptors, and Glutamate, excitatory receptors. In GABA receptors, alcohol substrates binds allosterically, which allows the GABA receptors to increase their inhibitory activity. Besides giving GABA receptors an extra inhibitory punch, alcohol substrates bind to glutamate receptors, which blocks its excitatory activity. Alcohol effects on both of these metabolic pathways obstructs the brain from making memories, making well thought out decisions, and controlling impulses after a long term use.[7]
Collaborative Study on Genetics of Alcoholism (COGA) identified alcohol dependence on chromosome 4p, where SNP genotyping, measurement of genetic variation, found GABRA2's association with alcoholism within European and African ancestries. Most of these findings were strongly associated with early alcohol use and along with drug dependence. Besides these findings, COGA investigators identified GABRA2 associated with impulsiveness and found other phenotypes affected by alcohol such as EEG-β.[8]
Adolescent behavior
The International Behavioural and Neural Genetics Society reviewed studies that found linkage between β1-subunits in GABA-A receptors and excitability in the reward sensitivity behavior brain region. Linkage between these two suggest that inadequate GABRA2 variants can cause the development of mental disorders, such as addiction. The addictive behaviors can be seen as aggressive and defiant, but most of these behaviors can be caused by both genetic and environmental factors.[9]
GABRA2 genes have been linked to various behavioral traits, such as an absence of impulse control. At least 11 single nucleotide polymorphisms, or SNPs, within the GARBRA2 gene have been correlated to impulsivity and four of which were also found in alcoholism. There was an elevated neuronal activation in the insula and the Nucleus accumbens.[9] In animals, such as rats, a relationship was found between elevated alcohol consumption and increased impulsivity to those exposed to stress at an early stage in life. This impulsivity can be reversed with pharmacological handling of GABA-A receptors containing GABRA2 in certain neurological areas.[9]
See also
References
- ↑ "GABRA2 gamma-aminobutyric acid type A receptor alpha2 subunit [Homo sapiens (human)"]. Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=2555.
- ↑ "Entrez Gene: GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=2555.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Hanns, S.J.; Möhler, Hanns (2007). The GABA Receptor. New York: Humana Press. pp. 23–31, 69–87, 87–111. ISBN 978-1-59745-465-0.
- ↑ 4.0 4.1 "The role of GABA(A) receptors in the development of alcoholism". Pharmacology Biochemistry and Behavior. New Insights Into the Function of GABAA Receptor Subtypes 90 (1): 95–104. July 2008. doi:10.1016/j.pbb.2008.03.007. PMID 18440057.
- ↑ 5.0 5.1 "α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders". Pharmacology & Therapeutics 136 (2): 142–152. November 2012. doi:10.1016/j.pharmthera.2012.08.006. PMID 22921455.
- ↑ "Anxiety disorders and GABA neurotransmission: a disturbance of modulation". Neuropsychiatric Disease and Treatment 11: 165–175. 2015-01-17. doi:10.2147/NDT.S58841. PMID 25653526.
- ↑ "Alcohol's effects on brain and behavior". Alcohol Research & Health 33 (1–2): 127–143. 2010. PMID 23579943.
- ↑ "Genetics and alcoholism". Nature Reviews. Gastroenterology & Hepatology 10 (8): 487–494. August 2013. doi:10.1038/nrgastro.2013.86. PMID 23712313.
- ↑ 9.0 9.1 9.2 "GABAA receptor subtype involvement in addictive behaviour". Genes, Brain and Behavior 16 (1): 149–184. January 2017. doi:10.1111/gbb.12321. PMID 27539865.
Further reading
- "α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders". Pharmacology & Therapeutics 136 (2): 142–152. November 2012. doi:10.1016/j.pharmthera.2012.08.006. PMID 22921455.
- "The role of the GABRA2 polymorphism in multiplex alcohol dependence families with minimal comorbidity: within-family association and linkage analyses". Journal of Studies on Alcohol and Drugs 68 (5): 625–633. September 2007. doi:10.15288/jsad.2007.68.625. PMID 17690794.
- "Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B (8): 854–860. December 2006. doi:10.1002/ajmg.b.30349. PMID 16894595.
- "Association of GABRA2 with drug dependence in the collaborative study of the genetics of alcoholism sample". Behavior Genetics 36 (5): 640–650. September 2006. doi:10.1007/s10519-006-9069-4. PMID 16622805.
- "The role of GABRA2 in risk for conduct disorder and alcohol and drug dependence across developmental stages". Behavior Genetics 36 (4): 577–590. July 2006. doi:10.1007/s10519-005-9041-8. PMID 16557364.
- "Alternative splicing and promoter use in the human GABRA2 gene". Brain Research. Molecular Brain Research 137 (1–2): 174–183. June 2005. doi:10.1016/j.molbrainres.2005.03.001. PMID 15950776.
- "Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5". Biochemical and Biophysical Research Communications 316 (3): 636–642. April 2004. doi:10.1016/j.bbrc.2004.02.098. PMID 15033447.
- "Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations". American Journal of Human Genetics 74 (4): 705–714. April 2004. doi:10.1086/383283. PMID 15024690.
- "theta, a novel gamma-aminobutyric acid type A receptor subunit". Proceedings of the National Academy of Sciences of the United States of America 96 (17): 9891–9896. August 1999. doi:10.1073/pnas.96.17.9891. PMID 10449790. Bibcode: 1999PNAS...96.9891B.
- "Evolution of GABA(A) receptor diversity in the human genome". Gene 227 (2): 213–222. February 1999. doi:10.1016/S0378-1119(98)00594-0. PMID 10023064.
- "Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors". Molecular Pharmacology 43 (6): 970–975. June 1993. PMID 8391122.
- "gamma-Aminobutyric acidA receptors displaying association of gamma 3-subunits with beta 2/3 and different alpha-subunits exhibit unique pharmacological properties". The Journal of Biological Chemistry 269 (17): 12993–12998. April 1994. doi:10.1016/S0021-9258(18)99974-6. PMID 8175718.
External links
- GABRA2+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
{{Navbox | name = GABA receptor modulators | title = GABA receptor modulators | state = collapsed | bodyclass = hlist | groupstyle = text-align:center;
| group1 = Ionotropic | list1 = {{Navbox|subgroup | groupstyle = text-align:center | groupwidth = 5em
| group1 = GABAA | list1 =
- Agonists: (+)-Catechin
- Bamaluzole
- Barbiturates (e.g., phenobarbital)
- BL-1020
- DAVA
- Dihydromuscimol
- GABA
- Gabamide
- GABOB
- Gaboxadol (THIP)
- Homotaurine (tramiprosate, 3-APS)
- Ibotenic acid
- iso-THAZ
- iso-THIP
- Isoguvacine
- Isomuscimol
- Isonipecotic acid
- Kojic amine
- Lignans (e.g., honokiol)
- Methylglyoxal
- Monastrol
- Muscimol
- Nefiracetam
- Neuroactive steroids (e.g., allopregnanolone)
- Org 20599
- PF-6372865
- Phenibut
- Picamilon
- P4S
- Progabide
- Propofol
- Quisqualamine
- SL-75102
- TACA
- TAMP
- Terpenoids (e.g., borneol)
- Thiomuscimol
- Tolgabide
- ZAPA
- Positive modulators (abridged; see here for a full list): α-EMTBL
- Alcohols (e.g., ethanol)
- Anabolic steroids
- Avermectins (e.g., ivermectin)
- Barbiturates (e.g., phenobarbital)
- Benzodiazepines (e.g., diazepam)
- Bromide compounds (e.g., potassium bromide)
- Carbamates (e.g., meprobamate)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- Dihydroergolines (e.g., ergoloid (dihydroergotoxine))
- Etazepine
- Etifoxine
- Fenamates (e.g., mefenamic acid)
- Flavonoids (e.g., apigenin, hispidulin)
- Fluoxetine
- Flupirtine
- Imidazoles (e.g., etomidate)
- Kava constituents (e.g., kavain)<!--PMID: 9776662-->
- Lanthanum
- Loreclezole
- Monastrol
- Neuroactive steroids (e.g., allopregnanolone, [[Chemistry:Cholecholesterol]], THDOC)
- Niacin
- Nicotinamide (niacinamide)
- Nonbenzodiazepines (e.g., β-carbolines (e.g., [[abecarnil), cyclopyrrolones (e.g., zopiclone), imidazopyridines (e.g., zolpidem), pyrazolopyrimidines (e.g., zaleplon))
- Norfluoxetine
- Petrichloral
- Phenols (e.g., propofol)
- Phenytoin
- Piperidinediones (e.g., glutethimide)
- Propanidid
- Pyrazolopyridines (e.g., etazolate)
- Quinazolinones (e.g., methaqualone)
- Retigabine (ezogabine)
- ROD-188
- Skullcap constituents (e.g., baicalin)
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal))
- Topiramate
- Valerian constituents (e.g., valerenic acid)
- Volatiles/gases (e.g., chloral hydrate, chloroform, [[Chemistry:Diethyl diethyl ether, Parparaldehyde]], sevoflurane)
- Antagonists: Bicuculline
- Coriamyrtin
- Dihydrosecurinine
- Gabazine (SR-95531)
- Hydrastine
- Hyenachin (mellitoxin)
- PHP-501
- Pitrazepin
- Securinine
- Sinomenine
- SR-42641
- SR-95103
- Thiocolchicoside
- Tutin
- Negative modulators: 1,3M1B
- 3M2B
- 11-Ketoprogesterone
- 17-Phenylandrostenol
- α5IA (LS-193,268)
- β-CCB
- β-CCE
- β-CCM
- β-CCP
- β-EMGBL
- Anabolic steroids
- Amiloride
- Anisatin
- β-Lactams (e.g., penicillins, cephalosporins, carbapenems)
- Basmisanil
- Bemegride
- Bicyclic phosphates (TBPS, TBPO, IPTBO)
- BIDN
- Bilobalide
- Bupropion
- CHEB
- Chlorophenylsilatrane
- Cicutoxin
- Cloflubicyne
- Cyclothiazide
- DHEA
- DHEA-S
- Dieldrin
- (+)-DMBB
- DMCM
- DMPC
- EBOB
- Etbicyphat
- FG-7142 (ZK-31906)
- Fiproles (e.g., fipronil)
- Flavonoids (e.g., amentoflavone, oroxylin A)
- Flumazenil
- Fluoroquinolones (e.g., ciprofloxacin)
- Flurothyl
- Furosemide
- Golexanolone
- Iomazenil (123I)
- IPTBO
- Isopregnanolone (sepranolone)
- L-655,708
- Laudanosine
- Leptazol
- Lindane
- MaxiPost
- Morphine
- Morphine-3-glucuronide
- MRK-016
- Naloxone
- Naltrexone
- Nicardipine
- Nonsteroidal antiandrogens (e.g., [[apalutamide, [[Chemistry:Bicalutbicalutamide, Enzalutenzalutamide, Chemistry:Flutamide|flut]]amide]], nilutamide)
- Oenanthotoxin
- Pentylenetetrazol (pentetrazol)
- Phenylsilatrane
- Picrotoxin (i.e., picrotin, picrotoxinin and dihydropicrotoxinin)
- Pregnenolone sulfate
- Propybicyphat
- PWZ-029
- Radequinil
- Ro 15-4513
- Ro 19-4603
- RO4882224
- RO4938581
- Sarmazenil
- SCS
- Suritozole
- TB-21007
- TBOB
- TBPS
- TCS-1105
- Terbequinil
- TETS
- Thujone
- U-93631
- Zinc
- ZK-93426
| group2 = GABAA-ρ | list2 =
- Agonists: BL-1020
- CACA
- CAMP
- Homohypotaurine
- GABA
- GABOB
- Ibotenic acid
- Isoguvacine
- Muscimol
- N4-Chloroacetylcytosine arabinoside
- Picamilon
- Progabide
- TACA
- TAMP
- Thiomuscimol
- Tolgabide
- Positive modulators: Allopregnanolone
- Alphaxolone
- ATHDOC
- Lanthanides
- Antagonists: (S)-2-MeGABA
- (S)-4-ACPBPA
- (S)-4-ACPCA
- 2-MeTACA
- 3-APMPA
- 4-ACPAM
- 4-GBA
- cis-3-ACPBPA
- CGP-36742 (SGS-742)
- DAVA
- Gabazine (SR-95531)
- Gaboxadol (THIP)
- I4AA
- Isonipecotic acid
- Loreclezole
- P4MPA
- P4S
- SKF-97541
- SR-95318
- SR-95813
- TPMPA
- trans-3-ACPBPA
- ZAPA
- Negative modulators: 5α-Dihydroprogesterone
- Bilobalide
- Loreclezole
- Picrotoxin (picrotin, picrotoxinin)
- Pregnanolone
- ROD-188
- THDOC
- Zinc
}}
| group2 = Metabotropic
| list2 =
| below =
- See also
- Receptor/signaling modulators
- GABAA receptor positive modulators
- GABA metabolism/transport modulators
}}
Original source: https://en.wikipedia.org/wiki/GABRA2.
Read more |